Nucala 100MG/ML 1ML 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTHJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,590.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,590.98 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nucala 100mg/ml injectable medication. The delivery order, issued December 16, 2025, with an ultimate completion date of December 17, 2025, represents a routine pharmaceutical procurement supporting Department of Defense medical supply requirements. No set-aside designation was applied to this award, indicating the contractor competed in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying comprehensive pharmaceutical products to military healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V contract, awarded November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The contractor's established performance across numerous delivery orders issued by the Defense Logistics Agency Medical Supply Chain division demonstrates its capability to supply diverse pharmaceutical categories including specialty biologics, oncology treatments, vaccines, and emergency medications to support global Department of Defense healthcare operations. As a critical supplier within the federal pharmaceutical supply chain since its System for Award Management registration in 2001, DMS Pharmaceutical Group has demonstrated consistent contract performance without identified subcontractor relationships in its award documentation.
Quick answers
Who was awarded contract SPE2DR26FBTHJ?
SPE2DR26FBTHJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FBTHJ worth?
The government has obligated $11,591 on SPE2DR26FBTHJ.
Is contract SPE2DR26FBTHJ an order under another contract?
Yes. SPE2DR26FBTHJ is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTHJ competed?
The extent of competition for SPE2DR26FBTHJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award